Elsevier

The Lancet

Volume 349, Issue 9062, 10 May 1997, Page 1365
The Lancet

Research Letters
Orally active prostacyclin analogue in primary pulmonary hypertension

https://doi.org/10.1016/S0140-6736(97)24019-5Get rights and content

References (5)

  • RJ Barst et al.

    A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

    N EnglJ Med

    (1996)
  • S Rich et al.

    The effect of high-dose calcium channel blockers on survival in primary pulmonary hypertension

    N EnglJ Med

    (1992)
There are more references available in the full text version of this article.

Cited by (128)

  • Antiplatelet strategies: past, present, and future

    2023, Journal of Thrombosis and Haemostasis
  • Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide

    2016, Seminars in Perinatology
    Citation Excerpt :

    There are limited data on its use in infants.52 Beraprost sodium (BPS, Dorner® 20 µg tablet, Toray Industries Inc, Tokyo, Japan) is an oral formulation developed in Japan with a half-life of 35–40 min, and has been shown to improve pulmonary hypertension in adults53,54 and children with congenital heart disease.55,56 In a case series of seven infants with PPHN refractory to alkali therapy and high frequency ventilation, beraprost reduced OI but also decreased systemic blood pressure by an average of 11 mmHg by 6 h.57 In this study, infants received 1 µg/kg of beraprost every 6 h.

  • A comparative study of PGI<inf>2</inf> mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor

    2013, Prostaglandins and Other Lipid Mediators
    Citation Excerpt :

    Unlike epoprostenol and iloprost, treprostinil has a long half-life, allowing its administration by continuous subcutaneous injection, thus avoiding the risk of infection related to continuous long term intravenous administration [14,15]. Beraprost is the first PGI2 analogue available as an oral formulation [16]. Currently, treprostinil and selexipag (and its metabolite MRE-269 = ACT-333679) are other orally available PGI2 mimetics in clinical development (Phase III) for the treatment of PAH [17,18].

  • Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension

    2012, Journal of Cardiology
    Citation Excerpt :

    The clinical effects of iloprost are similar to epoprostenol and treprostinil, and superior to them with regard to inducible infections. Beraprost was the first oral drug for PAH [20,21], although its effects subside after half a year of use. Therefore, beraprost has only been approved and used in Japan.

  • Pediatric Lung Transplantation

    2012, Pediatric Surgery, 2-Volume Set: Expert Consult - Online and Print
View all citing articles on Scopus
View full text